ArticleFrontiers in immunology2025
Case Report: Concurrent retinal vasculitis and optic neuritis in systemic lupus erythematosus.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinal Vaso-Occlusive Complications Associated with Systemic Lupus Erythematosus: A Systematic Review of Clinical Presentation and Visual Outcomes.Mediterranean journal of rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that can affect the ocular system, with retinal vasculitis and optic neuritis being rare but serious manifestations. We present a case of a 26-year-old female with newly diagnosed SLE who developed both retinal vasculitis and optic neuritis, leading to progressive visual impairment. She was successfully treated with methylprednisolone and rituximab, achieving significant visual recovery. A review of existing literature highlights the diagnostic challenges, pathophysiology, and optimal treatment strategies for such cases. Our findings emphasize the importance of early recognition and aggressive immunosuppressive therapy in improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.